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Summary
Young-onset calorie restriction (CR) in rodents decreases serum
IGF-1 concentration and increases serum corticosterone levels,
which have been hypothesized to play major roles in mediating
its anticancer and anti-aging effects. However, little is known on
the effects of CR on the IGF-1 system and cortisol in humans. To
test the sustained effects of CR on these key hormonal adapta-
tions, we performed a multicenter randomized trial of a 2-year
25% CR intervention in 218 nonobese (body mass index between
22 and 27.8 kg m2) young and middle-aged (20–50 years age
range) men and women. Average CR during the first 6 months
was 19.5  0.8% and 9.1  0.7% over the next 18 months of the
study. Weight loss averaged 7.6  0.3 kg over the 2-years period
of which 71% was fat mass loss (P < 0.0001). Average CR during
the CR caused a significant 21% increase in serum IGFBP-1 and a
42% reduction in IGF-1:IGFBP-1 ratio at 2 years (P < 0.008), but
did not change IGF-1 and IGF-1:IGFBP-3 ratio levels. Serum cortisol
concentrations were slightly but significantly increased by CR at
1 year only (P = 0.003). Calorie restriction had no effect on serum
concentrations of PDGF-AB and TGFb-1. We conclude, on the basis
of the present and previous findings, that, in contrast to rodents,
humans do not respond to CR with a decrease in serum
IGF-1 concentration or with a sustained and biological relevant
increase in serum cortisol. However, long-term CR in humans
significantly and persistently increases serum IGFBP-1
concentration.
Key words: calorie restriction; cancer; cortisol; IGF-1; IGFBP-1;
weight loss.
Introduction
Data from experimental and epidemiological studies indicate that insulin-
like growth factor (IGF)-1 and its binding proteins play a role in the
biology of aging and in the pathogenesis of several common cancers (Yu
& Rohan, 2000; Renehan et al., 2004; Yakar et al., 2005; Fontana et al.,
2010; Kopchick et al., 2014). Patients with acromegaly, who have high
growth hormone and IGF-1 levels, experience a 2-fold increased risk of
gastrointestinal cancers (Renehan et al., 2003), whereas patients with
congenital deficiencies in IGF-1 seem to be protected against the
development of cancer (Shevah & Laron, 2007; Guevara-Aguirre et al.,
2011). Data from several genetic animal models of longevity have shown
that reduced function mutations in the IGF-1 signaling pathway have
low circulating IGF-1 levels, reduced cancer incidence, and increased
maximal lifespan (Fontana et al., 2010). Moreover, in a study of 31
genetically diverse inbred mouse strains, the median lifespan was
inversely correlated with plasma IGF-1 levels (Yuan et al., 2009). IGF-1 is
a potent mitogenic growth factor, which promotes cell proliferation and
differentiation, and inhibits apoptosis (Yakar et al., 2005). The inhibition
of the IGF-1 pathway causes several cellular and metabolic adaptations,
including downregulation of growth pathways, upregulation of autop-
hagic and apoptotic pathways, increased resistance to multiple toxic
agents, and increased genome stability (Fontana et al., 2010; Bartke
et al., 2013).
Calorie restriction (CR) without malnutrition is one of the most
powerful interventions to slow aging and prevent cancer in laboratory
strains of rodents (Albanes, 1987; Fontana et al., 2010; Longo &
Fontana, 2010). Adult-onset moderate CR also reduces cancer incidence
by more than 50% in Rhesus monkeys (Colman et al., 2009; Mattison
et al., 2012). It has been hypothesized that the powerful inhibitory effect
of CR on spontaneous, chemically induced and radiation-induced tumors
can be mediated, at least in part, by a reduction in IGF-1 levels and an
increase in corticosteroid levels (Longo & Fontana, 2010). In rodents, CR
decreases serum insulin-like growth factor-1 (IGF-1) concentration by
20–40% and increases serum corticosterone levels by 30–50% (Breese
et al., 1991; Sabatino et al., 1991; Dunn et al., 1997). Both adrenalec-
tomy and IGF-I supplementation abrogate the protective effect of CR on
neoplastic progression (Pashko & Schwartz, 1992, 1996; Dunn et al.,
1997; Stewart et al., 2005). Data from two small short-term (6 and
12 months) randomized clinical trials and a cross-sectional observational
study have shown that CR does not increase serum cortisol or reduce
serum IGF-1 and IGF-1:IGFBP-3 ratio levels, unless protein intake is also
reduced (Weiss et al., 2006; Fontana et al., 2008; Redman et al., 2010;
Tam et al., 2014). However, there are currently no randomized
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controlled trials (RCT) in young–middle age lean or slightly overweight
men and women, evaluating the long-term effects of CR on serum IGF-
1, IGFBPs, and cortisol concentrations.
One of the purposes of this 2-year multicenter randomized controlled
trial (CALERIE) was to evaluate the effects of a 25% reduction in energy
intake in a large number of nonobese young and middle-aged men and
women on the IGF-1 axis, and other growth and hormonal factors
modulated by CR, which have been implicated in the biology of aging
and in the pathophysiology of cancer, such as PDGF-AB, TGF-b-1, and
cortisol.
Results
Of the more than 10 000 men and women assessed for eligibility, the
screening procedures excluded 45% of them for their age or body mass
index (BMI), 14% for health or medication reasons, and 30% refused to
participate due to concerns about their ability to adhere to the protocol,
and personal or study-related issues (Ravussin et al., 2015). Of the 238
participants who began baseline assessments, 220 were randomized,
218 started the assigned intervention, and 82% of CR and 95% of ad
libitum (AL), respectively, completed the study (Fig. 1). Table 1 presents
sex, age, race, and BMI data for the two groups. Analysis revealed no
significant differences between groups at baseline for these variables.
Intervention adherence, body weight, and composition
Detailed information regarding the observed adherence to the interven-
tion has been published previously (Ravussin et al., 2015). At baseline,
there was no difference in average energy intake (assessed as TDEE
during weight stability) between the CR [2467 (34) kcal day1] and AL
[2390 (45) kcal day1] groups (P = 0.15). In the CR group, energy intake
was reduced by 19.5 (0.8)% (480 kcal day1) during the first 6 months,
and by an average of 9.1 (0.7)% (234 kcal day1) below baseline for the
remaining 18 months of the study (P < 0.0001 vs. AL control group),
while in the control group average daily energy intake was unchanged
(Table 2). Weight loss averaged 8.3 (0.3) kg (11.5%) at 1 year and 7.6
(0.3) kg (10.4%) at 2 years in the CR group (P < 0.001), but did not
change significantly in the AL group (Table 2). Body fat measured by
dual-energy X-ray absorptiometry (DXA) decreased by 6.1 (0.2) kg at
1 year and 5.3 (0.3) kg at 2 years in the CR group (P < 0.001), but did
not change in the AL group. Fat loss accounted for ~71% of the weight
loss (Table 2).
Self-reported energy and nutrient intake
Seven-day food records showed that the CR group significantly restricted
their energy intake [279 (29) kcal day1 at 1 year and 216
(33) kcal d1 at 2 years], while the AL [83 (38) kcal day1 at 1 year
and 121 (43) kcal day1 at 2 years] group maintained its intake
(Table 3). Accordingly, intake of macronutrients such as fat also
decreased in the CR compared with the AL group, but protein intake
increased significantly (Table 3).
IGF-1 axis and other growth factors
The substantial and sustained increase in serum IGFBP-1 concentration
and the reduction in IGF-1:IGFBP-1 ratio in CR significantly exceeded
changes in AL (Table 4). Serum IGFBP-3 reductions in CR significantly
exceeded those in AL at 12 months (P = 0.018), but not at 24 months
(Table 4). In contrast, serum IGF-1, IGF-1:IGFBP-3 ratio and PDGF-AB
levels did not change significantly between groups at 12 and 24 months
(Table 4). Serum TGF-b1 decreased from baseline at 12 and 24 months
in CR (Table 4), but the declines did not differ significantly from the
change in AL. Serum cortisol concentration slightly but significantly
increased in the CR group at 12 months (P = 0.003), but not at
24 months (Table 4).
Fig. 1 CONSORT diagram.
Table 1 Demographic, anthropometric, and clinical characteristics at baseline for
the 218 participants who started the 2-year intervention




White 57 (76%) 111 (77.6%)
African American 11 (14.7%) 15 (10.5%)
Other 7 (9.3%) 17 (11.9%)
Age (years) 37.9 (6.94) 38.0 (7.34)
Height (m) 168.4 (8.31) 168.9 (8.60)
Baseline weight (kg) 71.5 (8.65) 72.0 (9.49)
Baseline BMI (kg m2) 25.1 (1.64) 25.2 (1.78)
Body fat (%) 33.6 (6.57) 32.9 (6.07)
FFM (kg) 47.6 (8.61) 48.5 (9.21)
Energy and macronutrient intake
Energy intake (kcal day1) 2045.3 (480.66) 2126.3 (558.60)
Protein (g kg1 day1) 1.2 (0.04) 1.2 (0.02)
Protein, % of energy 17.2 (3.48) 16.6 (3.04)
Fat, % of energy 34.7 (5.12) 33.5 (4.93)
Carbohydrates, % of energy 45.1 (6.33) 46.8 (6.48)
Laboratory values
IGF-1 (ng mL1) 183.1 (49.40) 175.5 (42.66)
IGFBP-1 (pg mL1) 4477 (5033.7) 5459 (6252.0)
IGFBP-3 (pg mL1) 2529 (502.7) 2459 (399.8)
IGF-1/IGFBP-3 ratio 0.07 (0.025) 0.07 (0.020)
IGF-1/IGFBP-1 ratio 0.10 (0.105) 0.08 (0.092)
PDGF-AB (ng mL1) 20.0 (6.01) 18.1 (6.97)
TGF-b1 (ng mL1) 30.6 (8.02) 28.9 (9.72)
Cortisol (lg dL1) 11.3 (5.91) 11.2 (4.92)
AL, ad libitum control group; CR, 25% calorie restriction group; FFM, fat-free
mass; FM, fat mass.
Values represent means (SD).
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Discussion
Research on aging and cancer mechanisms has shown that the IGF
pathway is deeply implicated in the biology of aging and in pathogenesis
of several common malignant and potentially deadly tumors (e.g., colon,
prostate, breast and ovarian cancer) (3) and that diet (e.g., CR)
influences cancer risk through this pathway (Renehan et al., 2004;
Fontana et al., 2010; Longo & Fontana, 2010; Guevara-Aguirre et al.,
2011). Most research data in this field have been derived from animal,
epidemiological and observational studies, because it is difficult and
expensive to conduct long-term randomized clinical trials in humans.
Thus, this is the first adequately powered randomized clinical trial to test
in nonobese humans the long-term effects of CR on the IGF-1 axis and
other growth factors implicated in the pathogenesis of cancer.
The findings of this clinical trial showed that, unlike in rodents (Breese
et al., 1991), long-term CR results in a significant and persistent increase
in serum IGFBP-1 and decrease in IGF-1:IGFBP-1 ratio levels, which
should translate into lower circulating levels of free IGF-1 and inhibition
of IGF-1 activity in humans. IGFBP-1 concentrations were 25.2% and
21% higher after 1 and 2 years of CR, respectively, resulting in a 42%
lower IGF-1:IGFBP-1 ratio level in the CR group at 2 years. This increase
in serum IGFBP-1 levels in our CR research volunteers may be mediated
by improved insulin sensitivity (Suikkari et al., 1988). In fact, serum
concentration of IGFBP-1, unlike IGFBP-3 which binds 75–90% of
circulating IGF-I, is heavily influenced by the metabolic (i.e., insulin
resistance, and insulin and glucagon levels) and nutritional (fasting and
refeeding) state of the individual. Excessive adiposity-induced insulin
resistance and compensatory hyperinsulinemia have been shown to
decrease hepatic synthesis of IGFBP-1, which translates into increased
concentrations of bioavailable IGF-1, without modifications in serum
total IGF-1 levels (Lukanova et al., 2001; Maddux et al., 2006). Patients
with type 1 diabetes have higher serum IGFBP-1 concentrations than
normoglycemic controls (Suikkari et al., 1988), and acute steady state
hyperinsulinemia lowers serum IGFBP-1 levels by 40–70% in normal
individuals (Yeoh & Baxter, 1988; Snyder & Clemmons, 1990). Moreover,
it has been shown that circulating levels of IGFBP-1 are acutely increased
by 3–4 fold in response to overnight fasting and decline rapidly after a
meal (Busby et al., 1988; Smith et al., 1995).
Fasting, but not long-term CR, lowers serum IGF-1 concentration in
humans into the range observed for growth hormone-deficient patients
(Thissen et al., 1994; Fontana et al., 2008; Redman et al., 2010).
Consistent with these previous human studies, we found that, unlike in
rodents, the reduction in energy intake in the CR group was not
accompanied by a decrease in serum IGF-1 concentration or IGF-1/
IGFBP-3 ratio, even in younger men and women. One possible
explanation for the lack of effect of CR on IGF-1 levels in this and other
studies may be the chronic high-normal intake of dietary proteins, which
was two-fold higher than the RDA median (i.e., 0.6 g kg1 day1). In a
previous study, we have shown that reducing protein intake from 1.6 to
0.95 g kg1 day1 was necessary to reduce serum IGF-1 concentrations
Table 2 Change from baseline in body composition at 12 and 24 months in AL













Baseline 71.5 (1.0) 72.0 (0.8) 0.978
D Month 12 0.7 (0.4) 0.105 8.4 (0.3) < 0.001 < 0.001
D Month 24 0.1 (0.5) 1.0 7.5 (0.4) < 0.001 < 0.001
Body mass index (kg m2)
Baseline 25.1 (0.2) 25.2 (0.2) 0.937
D Month 12 0.2 (0.1) 0.207 2.9 (0.1) < 0.001 < 0.001
D Month 24 0.1 (0.2) 1.0 2.6 (0.1) < 0.001 < 0.001
% Body fat
Baseline 33.6 (0.8) 32.9 (0.5) 0.336
D Month 12 0.47 (0.3) 0.254 5.5 (0.2) < 0.001 < 0.001
D Month 24 0.13 (0.3) 1.0 4.6 (0.3) < 0.001 < 0.001
Fat mass (kg)
Baseline 23.8 (0.6) 23.5 (0.4) 0.611
D Month 12 0.34 (0.3) 0.518 6.1 (0.2) < 0.001 < 0.001
D Month 24 0.38 (0.4) 0.564 5.3 (0.3) < 0.001 < 0.001
Fat-free mass (kg)
Baseline 47.6 (1.0) 48.5 (0.8) 0.475
D Month 12 0.3 (0.2) 0.131 2.2 (0.1) < 0.001 < 0.001
D Month 24 0.2 (0.2) 0.837 2.2 (0.2) < 0.001 < 0.001
†Baseline values are the observed mean (SE); change scores are the least-squares
adjusted means (SE) from the ITT repeated measures analysis.
‡Within-group P-value tests for a significant change from baseline to the follow-up
time point in that group; between-group P-value tests for a significant between-
group difference in the change score at the time point. All P-values reflect
Bonferroni corrections, truncated at 1.0, as appropriate (see text).
Table 3 Change from baseline in dietary energy intake and macronutrient












Energy intake (kcal day1)
Baseline 2045.3 (55.5) 2126.3 (46.7) 0.463
D Month 12 83.0 (38.6) 0.065 279.5 (29.3) < 0.001 < 0.001
D Month 24 121.1 (42.7) 0.010 216.3 (33.1) < 0.001 0.073
Protein intake (g kg1)
Baseline 1.2 (0.04) 1.2 (0.02) 0.951
D Month 12 0.002 (0.03) 1.0 0.11 (0.03) < 0.001 0.007
D Month 24 0.09 (0.04) 0.055 0.08 (0.03) 0.012 0.001
% Calories from protein
Baseline 17.2 (0.4) 16.6 (0.3) 0.252
D Month 12 0.8 (0.4) 0.123 1.8 (0.3) < 0.001 0.047
D Month 24 0.1 (0.4) 1.0 1.1 (0.3) 0.003 0.068
% Calories from fat
Baseline 34.7 (0.6) 33.5 (0.4) 0.034
D Month 12 0.2 (0.6) 1.0 4.8 (0.4) < 0.001 < 0.001
D Month 24 0.5 (0.6) 0.827 3.4 (0.5) < 0.001 < 0.001
% Calories from carbohydrates
Baseline 45.1 (0.7) 46.8 (0.5) 0.078
D Month 12 0.7 (0.7) 0.578 3.6 (0.5) < 0.001 < 0.001
D Month 24 0.8 (0.7) 0.482 2.4 (0.5) < 0.001 < 0.001
†Baseline values are the observed mean (SE); change scores are the least-squares
adjusted means (SE) from the ITT repeated measures analysis.
‡Within-group P-value tests for a significant change from baseline to the follow-up
time point in that group; between-group P-value tests for a significant between-
group difference in the change score at the time point. All P-values reflect
Bonferroni corrections, truncated at 1.0, as appropriate (see text).
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in individuals practicing severe CR (Fontana et al., 2008). We also found
that protein restriction, independently of caloric intake, strongly inhibits
tumor growth in human xenograft prostate and breast cancer animal
models, by lowering serum IGF-1 and reducing mTOR phosphorylation
(Fontana et al., 2013). Consistently, it has been shown that in humans
the variations of circulating IGF-1 levels during fasting and refeeding are
strongly linked with the rate of urinary urea excretion, a well-known
indicator of protein intake (Clemmons et al., 1981).
In this study, we also measured two growth factors, TGF-b-1 and
PDGF-AB, implicated in the pathogenesis of cancer (Silver, 1992;
Meulmeester & Ten Dijke, 2011), which have previously been shown
in observational studies to be reduced by long-term severe CR in humans
(Fontana et al., 2004; Meyer et al., 2006). Our findings confirmed that
CR induces a significant reduction in serum TGF-b-1 and PDGF-AB over
time, but the differences between groups were not significant. Data
from animal studies have shown that increased serum corticosterone
concentration may also play a role in the CR-induced protective effects
against cancer, as adrenalectomy completely reverses the tumor
inhibitory effect of CR in some studies (Pashko & Schwartz, 1992,
1996; Stewart et al., 2005). It has been hypothesized that a CR-induced
moderate increase in glucocorticoid concentrations may influence cancer
development by inhibiting inflammation and promoting the activation of
molecular chaperones (e.g., heat-shock proteins), which ensure pro-
teostasis (Sapolsky et al., 2000; Rhen & Cidlowski, 2005). Data from two
previous small, short-term studies have shown that CR-induced weight
loss does not increase cortisol concentration in overweight men and
women (Weiss et al., 2006; Tam et al., 2014). In contrast, this study
shows that 1 year of CR slightly but significantly increases serum cortisol
level in young and middle-aged lean or slightly overweight men
and women. This ~6% elevation in cortisol, however, was transient
because no change in serum cortisol concentration was detected after
2 years of CR.
In conclusion, data from this large randomized clinical trial showed
that long-term CR does not reduce serum IGF-1 concentration, but
causes a reduction in IGF-1 bioavailability by substantially and
persistently increasing IGFBP-1 levels in young and middle-aged lean or
slightly overweight men and women. These data also showed that long-
term CR results in mild and transient increase in serum cortisol
concentrations. More studies are needed to understand the biological
implications of these metabolic adaptations on cancer risk, health, and
longevity, and whether or not other nutritional interventions (e.g.,
protein restriction or intermittent fasting) reduce serum IGF1 concen-
tration in humans.
Experimental procedures
Figure 1 shows the CONSORT diagram which has been reported
previously (Ravussin et al., 2015). Briefly, CALERIE was an intensive
multicenter randomized, controlled trial with the aim of determining the
effects of 25% CR (a reduction in energy intake to 25% below the
individual’s baseline level) over a 2-year period in healthy volunteers.
Men were required to be between 20 and 50 years, and women
between 20 and 47 years, of age, with a BMI between 22 and
27.9 kg m2. The study protocol (NCT00427193) was approved by the
Institutional Review Boards of Washington University (St. Louis, MO,
USA), Tufts University (Boston, MA, USA), Pennington Biomedical
Research Center (Baton Rouge, LA, USA), and Duke University (Durham,
NC, USA). Study oversight was provided by a Data and Safety
Monitoring Board. The participants provided written informed consent.
Treatment assignment and intervention
After baseline testing, volunteers were randomized to 25% CR or
ad libitum control groups with a 2:1 allocation in favor of the CR group.
Randomization was stratified for site, sex, and BMI. The CR participants
were prescribed a 25% reduction in energy intake based on energy
requirements determined by doubly labeled water measurements over a
4-week period. Adherence to the prescribed 25% CR was calculated by
the degree to which the study volunteers attained a prescribed weight
loss trajectory (average at 1-year 15.5%, range of 11.9–22.1%) followed
by weight maintenance. Furthermore, the accurate level of CR was
retrospectively validated by measuring the total daily energy expenditure
(TDEE) by doubly labeled water and adjusting TDEE for changes in body
composition (Racette et al., 2012).
Table 4 Change from baseline in plasma concentrations of growth factors and













Baseline 183.1 (5.7) 175.5 (3.6) 0.589
D Month 12 19.6 (4.9) < 0.001 7.1 (3.7) 0.108 0.072
D Month 24 18.7 (4.1) < 0.001 15.1 (3.2) < 0.001 0.919
IGFBP-1 (pg mL1)
Baseline 4477 (585) 5459 (523) 0.088
D Month 12 409 (636) 1.0 1839 (474) < 0.001 0.065
D Month 24 616 (573) 0.568 1391 (443) 0.004 0.005
IGFBP-3 (ng mL1)
Baseline 2528 (58.4) 2459 (33) 0.338
D Month 12 1 (43) 1.0 124 (32) < 0.001 0.018
D Month 24 56 (49) 0.510 123 (38) 0.003 0.273
IGF-1/IGFBP-3 ratio
Baseline 0.10 (0.00) 0.10 (0.00) 0.942
D Month 12 0.008 (0.002) < 0.001 0.006 (0.002) 0.001 0.880
D Month 24 0.008 (0.002) < 0.001 0.009 (0.002) < 0.001 1.0
IGF-1/IGFBP-1 ratio
Baseline 0.102 (0.012) 0.078 (0.008) 0.064
D Month 12 0.007 (0.018) 1.0 0.046 (0.014) 0.002 0.088
D Month 24 0.020 (0.008) 0.018 0.045 (0.006) < 0.001 0.008
Cortisol (lg dL1)
Baseline 11.3 (0.69) 11.2 (0.41) 0.667
D Month 12 0.91 (0.46) 0.102 0.78 (0.35) 0.055 0.003
D Month 24 1.78 (0.51) 0.001 0.44 (0.39) 0.530 0.312
PDGF-AB (pg mL1)
Baseline 20 000 (699) 18 131 (583) 0.018
Month 12 398 (628) 1.0 26 (469) 1.0 1.0
Month 24 681 (515) 0.375 1465 (398) < 0.001 0.426
TGF-b1 (pg mL1)
Baseline 30 604 (932) 28 871 (813) 0.065
D Month 12 3169 (932) 0.002 3521 (697) < 0.001 1.0
D Month 24 5455 (707) < 0.001 6616 (549) < 0.001 0.356
†Baseline values are the observed mean (SE); change scores are the least-squares
adjusted means (SE) from the ITT repeated measures analysis.
‡Within-group P-value tests for a significant change from baseline to the follow-up
time point in that group; between-group P-value tests for a significant between-
group difference in the change score at the time point. All P-values reflect
Bonferroni corrections, truncated at 1.0, as appropriate (see text).
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Body weight and body composition
Body weight was measured fasting in the morning in a light gown. Fat
mass (FM) and fat-free mass (FFM) were measured by DXA using Hologic
4500A, Delphi W or Discovery A scanners (Hologic QDR 4500A; Hologic,
Bedford, MA). Scans were analyzed at University of California San
Francisco, also responsible for centralized quality control. Machine
performance was monitored with baseline and longitudinal phantom
cross-calibrations.
Dietary intake
Dietary intakes were determined using 6-day food diaries which were
analyzed with Nutrition Data System for Research (Minneapolis, MN,
USA).
Assays
Serum blood samples were obtained after fasting overnight and
analyzed in a central laboratory. Commercially available ELISA kits
were used to measure IGF-1, IGF-binding protein 1, (IGFBP-1) and
IGFBP-3 (DSL/Beckman Coulter, Brea, CA, USA), and PDGF-AB and
TGF-b-1 (R&D Systems, Minneapolis, MN, USA). Cortisol was measured
by chemiluminescent immunoassay (ADVIA Centaur, Bayer Health
Care, Deerfield, IL).
Statistical analysis
The same statistical methodologies used in the parent RCT were
applied (Racette et al., 2012). Briefly, Wilcoxon and the Fisher exact
tests were used to evaluate between-group differences with respect to
baseline characteristics. Repeated measures analysis of covariance was
applied with change from baseline as the dependent variable, and
treatment, time, and the treatment 9 time interaction as independent
variables; site, sex, BMI stratum, and the baseline value were included
as covariates. Hypotheses of specific interest, for example, between-
group differences at the individual time points and within-group
changes over time were tested by defining contrasts among the
regression parameters; predicted mean change  standard error are
the adjusted values from this model. For any outcome, type-I error
was controlled using a hierarchical gatekeeping strategy (Dmitrienko
et al., 2011). The treatment 9 visit interaction term was tested first. If
significant, then following standard statistical practice, between-group
differences at each time point were tested at a = 0.05. If not, the
treatment main effect was tested next. If significant, then between-
group differences at each time point were tested at a = 0.05.
Otherwise a Bonferroni correction was applied at each time point,
with the P-values adjusted by multiplying the nominal P-value by the
number of tests (truncated at 1.0) (Wright, 1992). Within-group
changes from baseline to the follow-up visits, however, fell
outside this hierarchy and were always protected by a Bonferroni
correction.
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